Moreover, FOXO1 is also engaged in taxane-mediated (docetaxel is the first-line chemotherapy in castration-resistant PC) attenuation of androgen receptor activation and progression to CRPC [43]. Here, FOXO1 is linked to pachyonychia congenita.